Luigi Alfonso Pannone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Luigi Alfonso Pannone has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Antimo Gioiello
University of Perugia
1 shared publication - Bruno Cerra
University of Perugia
1 shared publication - Emanuele Attolino
Research & Development Department, Newchem SpA, via Roveggia 47, 37136 Verona, Italy
1 shared publication - Emidio Camaioni
Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy
1 shared publication - Gianfranco Lopopolo
Research & Development Department, Newchem SpA, via Roveggia 47, 37136 Verona, Italy
1 shared publication - Riccardo Ronchetti
Department of Pharmaceutical Sciences (DSF), University of Perugia, Via del Liceo 1, 06123 Perugia, Italy
1 shared publication
Latest Publications
- Open Access
Multi-Gram Scale Synthesis and Characterization of Mometasone Furoate EP Impurity C
Mometasone furoate is a synthetic corticosteroid used in the treatment of skin inflammatory conditions, hay fever and asthma. The industrial manufacturing routes to mometasone furoate are generally accompanied by the formation of numerous process impurities that need to be detected and quantified, as requested by regulatory authorities. The ready availability of such impurities in the required quantity and purity is therefore essential for toxicological studies, analytical method development and process validation. Herein, we report the multi-gram scale preparation of 21′-chloro-(16′α-methyl-3′,11′,20′-trioxo-pregna-1′,4′-dien-17′-yl)-furan-2-carboxylate (mometasone furoate EP impurity C), one of the known impurities of mometasone furoate. This study also includes the systematic investigation of the final acylation step, as well as the characterization of the difuroate enol ether intermediate and its conversion to the target impurity C.
Open AccessMulti-Gram Scale Synthesis and Characterization of Mometasone Furoate EP Impurity C
Mometasone furoate is a synthetic corticosteroid used in the treatment of skin inflammatory conditions, hay fever and asthma. The industrial manufacturing routes to mometasone furoate are generally accompanied by the formation of numerous process impurities that need to be detected and quantified, as requested by regulatory authorities. The ready availability of such impurities in the required quantity and purity is therefore essential for toxicological studies, analytical method development and process validation. Herein, we report the multi-gram scale preparation of 21′-chloro-(16′α-methyl-3′,11′,20′-trioxo-pregna-1′,4′-dien-17′-yl)-furan-2-carboxylate (mometasone furoate EP impurity C), one of the known impurities of mometasone furoate. This study also includes the systematic investigation of the final acylation step, as well as the characterization of the difuroate enol ether intermediate and its conversion to the target impurity C.